Search clinical trials for: Indacaterol 150 µg

Total 8588 results

Novartis Pharmaceuticals

Completed

Efficacy and Safety of Indacaterol in Adults (40 Years and Above) With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

China, Australia, India
Novartis Pharmaceuticals

Completed

Cardiac Safety of Indacaterol

Chronic Obstructive Pulmonary Disease | Healthy Volunteers

United States
Novartis Pharmaceuticals

Completed

A Study to Evaluate the Effects of Indacaterol Maleate as a New Formulation in the Concept 1 Device

Asthma

Germany, United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (GLOW6)

Chronic Obstructive Pulmonary Disease (COPD)

Greece, Belgium, Bulgaria, Turkey, Hungary, Slovakia, Spain, United Kingdom, Russian Federation, Ireland
Novartis Pharmaceuticals

Completed

Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma (QAB149)

Asthma

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Indacaterol Acetate Delivered Via the Concept1 Inhalation Device in Children Greater or Equal to 6 and Less Than 12 Years of Age With Asthma

Asthma

South Africa, Belgium, Croatia, Turkey, Hungary, Colombia, Slovakia, Philippines, Russian Federation, Guatemala, Germany
Novartis

Completed

Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States, New Zealand, Belgium
Novartis

Completed

Dose Ranging Study of Indacaterol in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Japan
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD) (INSIST)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Germany, Spain, Turkey, Hungary, Czech Republic, India, Slovakia
Novartis Pharmaceuticals

Completed

Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Maleate Via Concept1 or Simoon Devices

Asthma

Germany, Netherlands, United Kingdom
Orion Corporation, Orion Pharma

Completed

Study to Compare Relative Bioavailability of 3 Indacaterol/Glycopyrronium Test Products and Reference Product (FORELLI)

Healthy Volunteers

Finland
Vanderbilt University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Optimization of Selenoprotein P in Chinese Subjects

Selenium Deficiency

China
Novartis Pharmaceuticals

Completed

Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Taiwan, Korea, Republic of, Japan, India, Hong Kong, Singapore
AstraZeneca
Parexel

Completed

A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects

Asthma

United States, Germany, South Africa, Ukraine, Japan, Hungary, Poland, Bulgaria
Pfizer

Completed

A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of Age (PICASSO)

RESPIRATORY SYNCYTIAL VIRUS (RSV)

United States
SkinJect, Inc.

Terminated

Dose Escalation Trial to Evaluate Dose Limiting Toxicity/Maximum Tolerated Dose of Microneedle Arrays Containing Doxorubicin (D-MNA) in Basal Cell Carcinoma (BCC)

Basal Cell Carcinoma

United States
Chiesi Farmaceutici S.p.A.

Completed

TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA (TRIMARAN)

Asthma

Germany
Axon Neuroscience SE

Unknown

A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia (AIDA)

Primary Progressive Nonfluent Aphasia

Germany
Laval University
Novartis

Completed

Ultibro® Versus Spiriva® Alone to Reduce Exertional Dyspnea in Patients With Moderate to Severe COPD (RED)

COPD

Canada
Novartis Pharmaceuticals

Completed

Exacerbation Study (INVIGORATE)

Chronic Obstructive Pulmonary Disease

Germany, Belgium, Colombia, Romania, South Africa, Italy, Hungary, Taiwan, Turkey, Switzerland, Australia, France, Israel, Sweden, China, Thailand, Estonia, Netherlands, Russian Federation, Slovakia, Spain, Argentina, Lithuania, Austria, Cana... and more
Helios Albert-Schweitzer-Klinik Northeim

Completed

Endocuff-assisted Versus Cap-assisted Versus Standard Colonoscopy (EC-Cap-SC)

Colorectal Polyps | Colorectal Adenomas

Germany, Poland
Pearl Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma

Asthma

United States
GlaxoSmithKline

Completed

Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants

Respiratory Syncytial Virus Infections

United States, Spain, Canada, Finland, Panama, South Africa, New Zealand, Australia, France
Dompé Farmaceutici S.p.A
Covance

Completed

Study to Evaluate Safety, Tolerability and Pharmacokinetics of rhNGF Eye Drops in Healthy Volunteers (NGF0112)

Healthy

Switzerland, United Kingdom
AstraZeneca
Parexel

Completed

Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871

Chronic Obstructive Pulmonary Disease COPD

Germany, United Kingdom
Yuan-Ming Luo

Completed

Comparison of Tai Chi and Pulmonary Rehabilitation on the Effect of Indacaterol in Treatment naïve COPD Participants

Chronic Obstructive Pulmonary Disease

China
BlueWillow Biologics
Porton Biopharma Ltd.

Completed

A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults (IN NE-rPA)

Anthrax

United States
Aalborg University

Completed

Characterization of New Human Models of Non-histaminergic Itch

Itch | Papain | Skin Prick Test (SPT)

Denmark
Butantan Institute
InCor - Instituto do Coração - HCFMUSP.

Withdrawn

Clinical Trial to Assess Safety and Immunogenicity of a Synthetic Vaccine Against Streptococcus Pyogenes

Rheumatic Fever
Orion Corporation, Orion Pharma

Completed

Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing (EASYRELIEF)

Asthma

Finland
Boehringer Ingelheim

Completed

Observational Study of Adherence to LABA / LAMA in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany
Novartis Pharmaceuticals

Completed

To Determine the Relationship Between Baseline Reversibility and the Efficacy of Indacaterol (REVERBREZ)

Chronic Obstructive Pulmonary Disease (COPD)

France
GlaxoSmithKline
CureVac

Completed

Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants

SARS-CoV-2

United States
Chiesi Farmaceutici S.p.A.

Completed

Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients

Asthma

Italy
Yonsei University

Completed

Lower Femtosecond Laser Energy Levels Lead to Better Visual Recovery After Small-incision Lenticule Extraction for Myopia

Myopia

Korea, Republic of
University Hospital, Basel, Switzerland

Recruiting

Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects (LBL)

Healthy

Switzerland
Novartis

Completed

26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Lung Diseases, Obstructive | Pulmonary Disease, Chronic Obstructive | COPD

United States, Germany, Spain, Argentina, Italy, Turkey, Canada, India, Sweden, Korea, Republic of, Taiwan, Puerto Rico
Morten Hostrup, PhD

Recruiting

U-LABA/ICS Effects on Exercise Performance, Indacaterol

Exercise Performance

Denmark
BlueWillow Biologics
National Institute of Allergy and Infectious Diseases (NIAID); University of...

Active, not recruiting

A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults (IN-NE-rH5)

Influenza, Pandemic

United States
Cryonove Pharma
CEISO; Dermatech; Sefako Makgatho Health Sciences University

Completed

Tolerance and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots.

Solar Lentigo | Post-inflammatory Hyperpigmentation | Senile Lentigo

South Africa
INSYS Therapeutics Inc

Withdrawn

Study to Explore Effectiveness of Sublingual Fentanyl Spray in Emergency Department Patients With Acute Pain

Acute Pain

United States
Statens Serum Institut

Completed

Trial on the Safety of a New Liposomal Adjuvant System, CAF01, When Given With the Tuberculosis Subunit Vaccine Ag85B-ESAT-6 as Two Injections With Two Months Interval to Healthy Adult Volunteers

Tuberculosis

Netherlands
Novartis Pharmaceuticals

Completed

Indacaterol EfectIveness In COPD Patients With Tuberculosis History (INFINITY)

Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis

Korea, Republic of
RVAC Medicines (US), Inc.

Terminated

Safety and Immunogenicity of RVM-V001 in Healthy Individuals Previously Vaccinated With BNT162b2 and mRNA-1273

COVID-19 | Infectious Disease

Australia
Mayne Pharma International Pty Ltd

Terminated

A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis

Lamellar Ichthyosis

United States, Spain, Canada, Germany, France, Australia, Israel, Ukraine, United Kingdom
Imperial College London
GlaxoSmithKline

Completed

Nasal LPS Challenge in Healthy Volunteers

Healthy

United Kingdom
University of Reading

Completed

Effects of A2 Milk on Gastrointestinal Function in Non-lactose Milk Intolerance

Milk Intolerance

United Kingdom
University of Milan
Fondazione Salvatore Maugeri

Completed

Acute Effect of Pulmonary Desufflation on Cardiac Performance in COPD Patients

Hyperinflation | COPD | Right Cardiac Failure

Italy
RVAC Medicines (US), Inc.

Terminated

Safety & Immunogenicity of RVM-V001/RVM-V002 or RVMV001+RVMV002 (Co Administered as Separate Injections) in Healthy Individuals

COVID-19 | Infectious Disease

Singapore
Novartis

Completed

Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks

Chronic Obstructive Pulmonary Disease

United States

3

Subscribe